Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Other analysts also recently issued research reports about the stock. Morgan Stanley reiterated an “overweight” rating and issued a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 13th. Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wedbush increased their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. HC Wainwright lowered their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Finally, Zacks Research downgraded shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $3.51 on Friday. The firm has a 50-day moving average of $3.36 and a 200-day moving average of $4.04. The company has a market cap of $947.66 million, a P/E ratio of -3.62 and a beta of 2.17. Sana Biotechnology has a one year low of $1.60 and a one year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, research analysts expect that Sana Biotechnology will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of institutional investors have recently modified their holdings of SANA. Balyasny Asset Management L.P. purchased a new stake in shares of Sana Biotechnology during the 4th quarter valued at approximately $6,834,000. Vanguard Group Inc. boosted its position in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after acquiring an additional 1,517,474 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the period. State Street Corp boosted its position in shares of Sana Biotechnology by 20.6% in the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after acquiring an additional 1,374,300 shares during the period. Finally, Baillie Gifford & Co. boosted its position in shares of Sana Biotechnology by 13.6% in the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after acquiring an additional 1,371,775 shares during the period. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.